Seeking medical miracles – A national leader in adult stem cell research makes its home on the Northshore.

Author Profile Image
Sign up for the free Daily Report email – local news about the people, companies and issues that impact business impact business in Baton Rouge and beyond.

When Dr. Gabriel Lasala makes presentations at international medical conventions, he frequently finds his audience is as amazed to learn where his biotech firm is located as they are to find out about the cutting-edge advances the four-year-old company is making in the field of stem cell research.

“People do not believe there could be anything like this in Louisiana,” Lasala says. “Especially in the country—outside of New Orleans.”

Yet, not only is TCA Cellular Therapy located in western St.Tammany Parish between Mandeville and Covington, but it is also one of the top 10 stem cell research firms in the U.S., according to the Food and Drug Administration.

Advertisement

“Nobody in Louisiana is doing what we do, and very few in the country,” says Lasala, president and medical director of TCA Cellular Therapy. “We’re one of just a handful of companies. It’s very exciting.”

Lasala founded the company in 2006, after recognizing the tremendous potential that stem cell therapy has for treating a host of injuries and diseases, particularly heart disease. That’s how he first became interested in the field. The Argentine-born cardiologist, who was trained at the University of Mississippi and has lived in south Louisiana for 14 years, heard about stem cell therapy in the early 2000s after German doctors used adult stem cells to reverse the effects of cardiovascular disease.

In 2004, he recruited Dr. Jose Minguell, Ph.D., a world-renowned molecular biologist from Chile, to work with him in developing treatments that could be used in the U.S. Over the course of the next two years, Minguell devised several protocols to treat patients with various cardiovascular diseases using stem cells harvested from the patients’ own bodies.

After getting approval for the protocols from the FDA, Lasala set about finding private investors, most of whom are physicians and business people based in Louisiana. In 2006, the company was officially formed, and Lasala began treating patients. To date, the treatments have produced incredibly positive results, he says.

A case in point is Rodney Schoenhardt of Metairie. He suffered from critical limb ischemia, a condition where blood flow to the leg is so restricted by artery blockage that pain is severe and amputation may be necessary. Schoenhardt’s previous physician was considering that drastic step, when Lasala began treating him, injecting his legs with his own stem cells to stimulate the growth of new blood vessels.

The procedure proved so successful that Schoenhardt’s pain is gone and the wheelchair he was using to get around is now collecting dust in his garage.

More recently, the company expanded its scope and established a neurological division. Last August, two patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) and one patient with a spinal cord injury were treated with infusions of their own adult stem cells, which were separated, purified and multiplied in TCA Cellular Therapy’s laboratory. The trials are the only U.S. FDA clinical trials in which patients receive their own cells for the treatment of ALS and spinal cord injury.

Such treatments are still in the clinical testing stage, which means they are not yet commercially available and, therefore, not covered by insurance. The industry is still young and some people are still skeptical.

A bigger problem is that many opinions about stem cell research and therapy have been colored by the controversy over using embryonic stem cells for research and treatments. Lasala is quick to point out that TCA Cellular Therapy uses only adult-harvested stem cells.

Lasala is bullish not only on the industry, but also on the potential it has for economic development in St. Tammany Parish and southeast Louisiana—especially given the state’s investment in promoting the biomedical industry.

“If we capture only 1% of patients suffering from the cardiovascular diseases we are studying, the area could see an annual impact of at least $8 billion, and the positive effects of our neurological studies would be immeasurable,” Lasala says.

Even if those estimates are on the high side, it’s clear the industry and the company have a lot to offer Louisiana. But competition is fierce, as the race to commercialize stem cell therapies for medical applications is intense.

The company anticipates its first therapy, a combination adult stem cell therapy to treat critical limb ischemia, will reach market in 2013, and Lasala is working tirelessly to build what he believes could become one of the next great meccas of medical research and treatment.

Says Lasala: “The North Shore to me is a great area to create what my dream is—a center of stem cell therapies.”

Discussion (0)

From Our Partners

Daily Report Poll

ASK AI

Ask anything about Baton Rouge business